

# Protecting and Improving the Health of Iowans

Kim Reynolds, Governor

Adam Gregg, Lt. Governor

Kelly Garcia, Interim Director

# **COVID-19 Vaccine Information Brief**

February 12, 2021

Changes to the document from the previous version are highlighted in yellow.

## Six Doses of Pfizer COVID-19 Vaccine in Each Vial

On February 15, 2021, all federal systems will be updated to account for the sixth dose of vaccine in each Pfizer vial. Allocations received beginning on Tuesday February 16<sup>th</sup> will be in increments of 1,170 doses. IRIS has already been updated in anticipation of this change and orders of Pfizer vaccine received after February 16th will automatically be accepted into provider inventories in increments of 1,170 doses. INVENTORY NOTE: Current inventory of Pfizer vaccine will not change and will still be counted as 5 doses per vial.

# Interim Clinical Considerations for Use of mRNA COVID-19 Vaccines

CDC released updated clinical guidance related to mRNA vaccines. The updated guidance can be found at Interim Clinical Considerations for Use of mRNA COVID-19 Vaccines Currently Authorized in the United States | CDC.

# Summary of recent changes (last updated February 10, 2021):

- New recommendations for preventing, reporting, and managing mRNA COVID-19 vaccine administration errors (Appendix A).
- Clarification on contraindications and precautions. Persons with a known (diagnosed) allergy to
  PEG, another mRNA vaccine component, or polysorbate, have a contraindication to vaccination.
  Persons with a reaction to a vaccine or injectable therapy that contains multiple components,
  one of which is PEG, another mRNA vaccine component or polysorbate, but in whom it is
  unknown which component elicited the immediate allergic reaction have a precaution to
  vaccination.
- Updated information on delayed, local injection-site reactions after the first mRNA vaccine dose. These reactions are neither a contraindication or precaution to the second dose.
- Updated quarantine recommendations for vaccinated persons. Fully vaccinated persons who
  meet criteria will no longer be required to quarantine following an exposure to someone with
  COVID-19. Additional considerations for patients and residents in healthcare settings are
  provided.
- Additional information and updated recommendations for testing for TB infection. TB testing
  can be done before or at the same time as mRNA COVID-19 vaccination, or otherwise delayed
  for ≥4 weeks after the completion of mRNA COVID-19 vaccination.

## Johnson & Johnson COVID-19 Vaccine

Johnson & Johnson submitted an application to the U.S. Food and Drug Administration (FDA) requesting Emergency Use Authorization (EUA) for its investigational single-dose Janssen COVID-19 vaccine candidate. An independent FDA panel will review Johnson & Johnson's data and is scheduled to meet on February 26, 2021 to discuss the EUA. If the authorization is granted, the Advisory Committee of Immunization Practices (ACIP) would meet to provide vaccine clinical recommendations.

#### Vaccinate with Confidence

CDC released updated <u>resources</u> aimed at building confidence in COVID-19 vaccines.

# **Updated Pre-Vaccination Screening Form in Spanish**

- <u>Prevaccination Screening Form- English</u>
- Prevaccination Screening Form-Spanish

## **COVID-19 Vaccination Communication Toolkits**

- For Medical Centers, Clinics, Pharmacies, and Clinicians
- For Healthcare Professionals and Pharmacists
- For LTCF Administrators and Leadership
- For Employers of Essential Workers
- For Staff of Organizations Serving Communities

# **Iowa Department of Public Health Vaccine Shortage Order**

The <u>Phase 1B Supplemental Vaccine Shortage Order</u> shortage order has been updated effective January 21, 2021. Iowa Healthcare providers shall only vaccinate persons who are included in a priority designation which has been activated by IDPH. Healthcare providers are prohibited from vaccinating any persons not included in a priority designation.

# **Disposal and Reporting of Nonviable COVID-19 Vaccine**

It is critical to account for every dose of COVID-19 vaccine, even doses that have expired or been wasted. The COVID-19 vaccination provider agreement states the provider must dispose of wasted COVID-19 vaccines according to the jurisdiction's procedures. Sites should dispose of COVID-19 vaccine waste in accordance with local regulations and processes currently used to dispose of regulated medical waste. In addition, COVID-19 vaccine program requirements include providers reporting wastage (e.g., unused, spoiled, or expired) information to IRIS. IRIS instructions on <u>Adjusting COVID-19 Vaccine Inventory for Wastage</u> are available on the Vaccine webpage.

## **COVID-19 Vaccine Administration Data Visualization**

The Iowa Department of Public Health (IDPH) is sharing data on statewide COVID-19 vaccine administration. These updates will be published each week on Monday, Wednesday and Friday. Reports will initially be static visualizations, including high-level information on vaccine administration

totals, as well as county-level information. The current update and future dashboard will be housed on the existing <a href="https://coronavirus.iowa.gov">https://coronavirus.iowa.gov</a> website <a href="here">here</a>. Iowa is currently performing amongst the highest in the nation for vaccine administration compared to the number of vaccine doses allocated. The CDC is tracking state vaccine information can be found <a href="here">here</a>.

#### CDC COVID Data Tacker

CDC has released the COVID Data Tracker. The <u>Vaccinations tab</u> on the tracker shows overall US COVID-19 vaccine distribution and administration. State views for total doses distributed are also available.

# Additional Doses of COVID-19 Vaccine per Vial

The Food and Drug Administration (FDA) has advised it is acceptable to use every full dose of COVID-19 vaccine obtainable from each vial of vaccine. However, since the COVID-19 vaccines do not contain preservatives, it is critical to note any further remaining vaccine that does not constitute a full dose should not be pooled from multiple vials to create a dose. <a href="IRIS">IRIS</a> instructions are available to determine if additional vaccine inventory adjustments are required. Contact the IRIS Help Desk at 800-374-3958 with questions regarding vaccine inventory.

#### **Moderna Clinical Guidance**

- Moderna Call Center available 8am to 8pm EST, Monday-Friday @ 1-866-663-3762
- <u>Letter of Authorization</u>
- EUA Fact Sheet for Healthcare Providers Administering Vaccine
- EUA Fact Sheet for Vaccine Recipients and Caregivers
- Moderna COVID-19 Vaccine webpage
- Interim Clinic Considerations for Use of Moderna COVID-19 Vaccine
- Moderna COVID-19 Vaccine Preparation and Administration Summary
- Freezer Temperature Log- Fahrenheit
- Freezer Temperature Log- Celsius
- Translations of EUA Fact Sheet for Recipients and Caregivers
- COVID-19 Vaccine Clinical FAQs
- Expiration date tracker
- Beyond use date tracking labels for refrigerator storage
- Vaccine storage and handling summary
- Vaccine storage and handling labels

## **Pfizer Clinical Guidance**

- Pfizer Call Center available 8am to 8pm EST, Monday-Friday @ 1-800-438-1985
- Letter of Authorization
- EUA Fact Sheet for Healthcare Providers Administering Vaccine

- <u>EUA Fact Sheet for Vaccine Recipients and Caregivers</u>
- Translations of EUA Fast Sheet for Recipients and Caregivers
- <u>Pfizer FAQs Pfizer-BioNTech COVID-19 Vaccine webpage</u>
- Interim Clinic Considerations of Use of Pfizer COVID-19 Vaccine
- Interim Considerations: Preparing for the Potential Management of Anaphylaxis at COVID-19
   Vaccination Sites
- <u>Pre-Vaccination Screening Form for Pfizer COVID-19 Vaccine</u>
- Pfizer COVID-19 Vaccine Preparation and Administration Summary
- Ultra-Cold Temperature Log- Fahrenheit
- <u>Ultra-Cold Temperature Log Celsius</u>
- <u>Pfizer On Demand Training</u> self-paced training module for healthcare professionals administering Pfizer COVID-19 vaccine. Continuing education is available.

## **CDC COVID-19 Vaccination Information for Consumers**

- What to expect at your vaccination appointment
- What to expect after getting vaccinated
- Benefits of Getting a COVID-19 Vaccine
- How COVID-19 Vaccines Work
- Myths and Misconceptions about COVID-19 Vaccines
- Frequently Asked Questions about COVID-19 Vaccination

### V-safe After Vaccination Health Checker

V-safe is a smartphone-based tool that uses text messaging and web surveys to provide personalized health check-ins after an individual receives a COVID-19 vaccination. V-safe web pages feature information on how to register and complete a v-safe health check-in (including step-by-instructions with images), troubleshooting, FAQs, and contact information for technical support. These web pages will be continuously updated with additional resources.

- V-safe information sheet and poster: Posted on the Vaccine webpage and available in 5 languages: English, Spanish, Korean, Vietnamese, and Simplified Chinese
- **V-safe** after vaccination health checker website
- V-Safe Print Resources
- Vaccine Adverse Event Reporting System (VAERS)

## **CDC COVID-19 Vaccination Resources**

- COVID-19 Vaccination Planning resources for healthcare professionals
- Frequently Asked Questions about COVID-19 Vaccination
- COVID-19 Vaccines and Severe Allergic Reactions
- Vaccination Considerations for People who are Pregnant or Breastfeeding
- CDC COVID-19 Vaccine Website

- COVID-19 ACIP Vaccine Recommendations
- Toolkit for Medical Centers, Clinics, and Clinicians
- Engaging in Effective COVID-19 Vaccine Conversations
- Toolkit for Medical Centers, Clinics, and Clinicians
- Answering Patient Questions
- Post-vaccination considerations for healthcare personnel
- <u>Post-vaccination considerations for long-term care residents</u>
- Ensuring COVID-19 Vaccines Work | CDC
- Facts about COVID-19 Vaccines
- How CDC Is Making COVID-19 Vaccine Recommendations | CDC
- Vaccine Education and Training for Healthcare Professionals | CDC
- <u>COVID-19 Vaccination Resources</u>
- COVID-19 Vaccine Training Module for Healthcare Providers
- Best Practices on Vaccine Storage and Handling
- <u>Different COVID-19 Vaccines</u>

### **IDPH COVID-19 Vaccination Resources**

- <u>IDPH COVID-19 Vaccine Website</u> Includes web-based training courses, videos, job aids and references regarding vaccine administration, general best practice guidelines for immunizations and vaccine storage and handling.
- Administration of COVID-19 Vaccine County/State of Residence Guidance This memo
  outlines the administration of COVID-19 vaccine by Iowa healthcare organizations to individuals
  regardless of permanent place of residence (county or state) or where the individual is seeking
  vaccination. In addition, receipt of COVID-19 vaccine does not require proof of U.S. citizenship.
  This is also available on HAN.
- Consent Form Sample The Federal Government does not require consent for the administration of COVID-19 vaccine. This document has been emailed to all enrolled COVID-19 Vaccine Providers and is available on HAN.
- **Declination Form Sample** A sample declination form is available to assist partners in the development of organization specific forms. This document has been emailed to all enrolled COVID-19 Vaccine Providers and is available on HAN.

### **MMWRs and Interim Guidance**

• On February 9, 2021 an MMWR article titled, <u>"COVID-19 Vaccination Intent, Perceptions, and Reasons for Not Vaccinating Among Groups Prioritized for Early Vaccination- United States, September and December 2020" was published.</u>

- On February 5, 2021 an MMWR article titled, <u>"Early COVID-19 First-Dose Vaccination Coverage Among Residents and Staff Members of Skilled Nursing Facilities Participating in the Pharmacy Partnership for Long-Term Care Program United States, December 2020–January 2021" was published.
  </u>
- On February 5, 2021 an MMWR article titled, "Demographic Characteristics of Persons
   Vaccinated During the First Month of the COVID-19 Vaccination Program United States,
   December 14, 2020—January 14, 2021" was published.
- On January 22, 2020 an MMWR article titled, "Allergic Reactions Including Anaphylaxis
   After Receipt of the First Dose of Moderna COVID-19 Vaccine United States,
   December 21, 2020-January 10, 2021" was published.
- On January 6, 2021 an MMWR article titled, <u>"Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioTech COVID-19 Vaccine United States, December 14-23, 2020"</u> was published.
- On December 20, 2020 an MMWR article titled, <u>"The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Moderna COVID-19 Vaccine United States, December 2020"</u> was published.
- On December 13, 2020 an MMWR article titled, "<u>The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine United States, December 2020</u>" was published.
- On December 13, 2020 an MMWR article titled, "<u>The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine United States, December 2020</u>" was published.
- On December 3, 2020 an MMWR article titled, "<u>The Advisory Committee on Immunization</u>
   Practices' Interims Recommendation for Allocating Initial Supplies of COVID-19 Vaccine United
   <u>States, 2020</u>" was published.
- The "Interim Considerations for COVID-19 Vaccination of Healthcare Personnel and Long-Term Care Facility Residents" was released.
- On November 23, an MMWR article titled "<u>The Advisory Committee on Immunization Practices</u>
   <u>Ethical Principles for Allocating Initial Supplies of COVID-19 Vaccine United States, 2020</u>" was published.

## **IDPH COVID-19 Vaccine Information Resources**

- **COVID-19 Vaccine Call Center** IDPH has established a healthcare provider COVID-19 Vaccine Call Center. To reach the COVID-19 Vaccine Call Center, call **1-800-831-6293**, **Option 1**.
- **COVID-19 Vaccine Email** IDPH has set up a COVID-19 Vaccine Email to respond specifically to questions from healthcare providers regarding COVID-19 vaccine. Vaccine questions can be emailed to: <a href="mailto:coviD19Vaccine@idph.iowa.gov">coviD19Vaccine@idph.iowa.gov</a>.
- **COVID-19 Call Center for the General Public** Questions from the general public regarding COVID-19 vaccines can be directed to 211.

# Federal Pharmacy Partnership Strategy for COVID-19 Vaccination Program

- HHS is partnering with pharmacies to increase access to COVID-19 vaccine supply increases and vaccines are recommended beyond the initial populations. Pharmacy partners will sign the COVID-19 Vaccination Program Provider Agreement at the federal level.
- Pharmacy partners will directly order and receive allocation of COVID-19 vaccine from the federal government. Timing and scale of activation (how many partners, how many stores) will depend on various factors, including vaccine supply.
- Activation based on a national scale, with select pharmacy partners directly ordering COVID-19 vaccine from CDC. CDC is working to activate the program the week of February 8, 2021.
- Pharmacy partners must report COVID-19 vaccine inventory in each store via VaccineFinder and report COVID-19 vaccine doses administration to IRIS.

# **Vaccine Shipping Resources**

• Below is contact information to help with addressing vaccine delivery issues.

I need help with	Contact
Pfizer vaccine shipment has a problem	Pfizer Customer Service Phone # (800) 666-7248 Email: cvgovernment@pfizer.com
Pfizer ancillary kit has a problem	McKesson Customer Service Phone #: 833-272-6634 Email: SNSSupport@McKesson.com
Moderna vaccine shipment has a problem	Vaccine Viability – Temperature Excursions during shipment for McKesson Specialty Distributed COVID Vaccine  1. Supports calls/emails from provider/admin sites and awardee or federal/pharmacy ordering points of contact.  2. Questions/concerns about vaccine viability issues during shipment must be reported on the same day as delivery.  Phone: (833) 272-6635 Monday – Friday, 8 a.m 8 p.m. ET Email: COVIDVaccineSupport@McKesson.com (only send email if after hours)
Moderna ancillary kit has a problem	Need to verify - McKesson Customer Service Phone #: 833-272-6634 Email: SNSSupport@McKesson.com